Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

181.14 +4.08 (+2.30%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
71 72 Next >
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
With an already tense situation becoming even more troubling, now’s the time to consider blue-chip dividend stocks to buy. 
Via InvestorPlace
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
Via Investor's Business Daily
Is AbbVie a Millionaire Maker?
Everything is going according to plan, and more growth is on the way. 
Via The Motley Fool
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Smart Money Is Betting Big In ABBV Options
Via Benzinga
What's Going On AbbVie Stock On Friday?
AbbVie releases interim analysis on atogepant, an oral migraine prevention drug. Key findings show significant reductions in migraine days and consistent safety profile. Atogepant, known as Qulipta... 
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a... 
Via Benzinga
AbbVie Unusual Options Activity For April 05
Via Benzinga
Smart Money Is Betting Big In ABBV Options
Via Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks. 
Via The Motley Fool
Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year
These seven dividend stocks provide a base for $50,000 in income per year for dedicated investors with patience. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements... 
Via Benzinga
The 3 Best Stocks to Buy in April 2024
With market dynamics shifting in the wind, concerned investors may want to target these ideas for best stocks to buy in April. 
Via InvestorPlace
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira. 
Via Investor's Business Daily
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
These stocks can deliver powerhouse portfolio growth in the years ahead. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
From Brodsky & Smith LLC
Via GlobeNewswire
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations. 
Via The Motley Fool
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
These advantaged businesses have what it takes to keep raising their payouts. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio
The dividend kings are excellent stocks with which to establish an income portfolio with these three dividend king stocks standing out. 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.